Lantheus Holdings (LNTH) Other Non-Current Assets (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Other Non-Current Assets came in at $61.7 million in Q1 2026, up 69.31% year-on-year from $36.5 million in Q1 2025, and down 23.53% on a QoQ basis from $80.7 million in Q4 2025.
Lantheus Holdings (LNTH) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Other Non-Current Assets data on file, last reported at $61.7 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 69.31% year-over-year to $61.7 million in Q1 2026; TTM through Mar 2026 was $61.7 million, a 69.31% increase from a year earlier, with the FY2025 full-year figure at $80.7 million, up 82.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $61.7 million, down from $80.7 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for LNTH reached as high as $80.7 million in Q4 2025 and fell as low as $7.2 million in Q3 2023.
- Historically, Other Non-Current Assets has averaged $32.7 million across 5 years, with a median of $36.5 million in 2025.
- Across the five-year window, Other Non-Current Assets plunged 82.94% in 2023 and surged 650.4% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $34.4 million in 2022, then tumbled by 79.16% to $7.2 million in 2023, then jumped by 517.92% to $44.2 million in 2024, then surged by 82.52% to $80.7 million in 2025, then slipped by 23.53% to $61.7 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $61.7 million in Q1 2026, $80.7 million in Q4 2025, and $53.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | 169,000.00 |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Lantheus Holdings | 6.97 Bn | 6.47 Bn | 230.92 Mn | 61.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.74 Mn |
| Dec 31, 2025 | 80.74 Mn |
| Sep 30, 2025 | 53.72 Mn |
| Jun 30, 2025 | 36.39 Mn |
| Mar 31, 2025 | 36.47 Mn |
| Dec 31, 2024 | 44.24 Mn |
| Sep 30, 2024 | 7.16 Mn |
| Jun 30, 2024 | 7.16 Mn |
| Mar 31, 2024 | 7.16 Mn |
| Dec 31, 2023 | 7.16 Mn |
| Sep 30, 2023 | 7.16 Mn |
| Jun 30, 2023 | 39.13 Mn |
| Mar 31, 2023 | 7.20 Mn |
| Dec 31, 2022 | 34.36 Mn |
| Sep 30, 2022 | 41.63 Mn |
| Jun 30, 2022 | 42.16 Mn |
| Mar 31, 2022 | 42.20 Mn |
| Dec 31, 2021 | 38.76 Mn |
| Sep 30, 2021 | 45.29 Mn |
| Jun 30, 2021 | 61.87 Mn |